CANF (Can-Fite BioPharma, Ltd.) Long-Term Debt

Graphic logo of Can-Fite (CANF)

Can-Fite BioPharma is developing a global network through licensing agreements with distributors to promote treatments for liver cancer and psoriasis. The current patient base in Europe is expanding through Piclidenoson trials, while FDA approval will enable entry into the mass market. The daily price action, where the indicator stands at 0.00, confirms the impact of strict FDA oversight and the patent protection of the drugs.

CANF Can-Fite BioPharma: Company Long-Term Debts in the range 07/04/2022 - 10/28/2026

Analytical breakdowns for Can-Fite BioPharma

- price and consensus price forecast:
Share Price canfite.com|CANF - Analyst Consensus Forecast
- market capitalization data:
Market Value Can-Fite BioPharma|CANF - Total Company Value
- book capitalization data:
Accounting Value of a Share Can-Fite BioPharma|CANF - Book Capitalization|Market Capitalization to Book Value Ratio canfite.com|CANF - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Can-Fite BioPharma|CANF - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Can-Fite|CANF - Company Debts|Debts to Book Value Can-Fite BioPharma|CANF - Company Long-Term Debt|Company Short-Term Indebtedness Can-Fite BioPharma
Fundamental valuation:canfite.com (CANF)
Mass-produced product of Can-Fite

This indicator aggregates the issuer's multi-year credit obligations, allowing for an assessment of financial leverage stability and default risk through the lens of long-term debt load. By analyzing the firm's long-term borrowed capital, investors can track the borrowing dynamics required by Can-Fite BioPharma (CANF) to finance costly research and development in oncology and inflammatory liver disease therapies.

Competitor analysis

Company Long-Term Indebtedness incyte.com INCY|HCM (HUTCHMED) - Company Long-Term Debts|NUVB: Long-Term Debt|Company Long-Term Debt Day One Bio DAWN|Monopar Corp (MNPR) - Company Long-Term Loans and Borrowings|INBX (Inhibrx Biosciences) - Company Long-Term Debts|Company Long-Term Debts IMAB|Company Long-Term Debt Fennec Pharmaceuticals Inc. (FENC)|Company Long-Term Debt herontx.com HRTX|Company Long-Term Liabilities Nuvectis|Coherus BioSciences - Company Long-Term Loans and Borrowings|CRBP (Corbus Pharmaceuticals) - Company Long-Term Debt|CRDF: Long-Term Debt|Company Long-Term Debt BeyondSpring|BioAtla (BCAB) - Company Long-Term Indebtedness|Company Long-Term Debts LIXT|Company Long-Term Liabilities CTXR|Cellectar Biosciences - Company Long-Term Debt|Long-Term Debt BLRX (biolinerx.com)|Company Long-Term Debt Aprea Therapeutics, Inc. APRE|Kazia Therapeutics Ltd - Company Long-Term Debt|SLXN (Silexion) - Company Long-Term Debt|NCNA - Long-Term Debt|Company Long-Term Debts CMRX (Chimerix, Inc.)|Long-Term Indebtedness cyclacel.com|Company Long-Term Liabilities GTHX (G1 Therapeutics Inc.)|Long-Term Debt Kronos Bio Inc (KRON)|Kintara (KTRA) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings Oncternal Corp ONCT|Company Long-Term Liabilities Portage Biotech Inc. (PRTG)